Gawałko Monika, Kapłon-Cieślicka Agnieszka, Hohl Mathias, Dobrev Dobromir, Linz Dominik
1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
Department of Cardiology, Maastricht University Medical Centre and Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
Int J Cardiol Heart Vasc. 2020 Oct;30:100631. doi: 10.1016/j.ijcha.2020.100631. Epub 2020 Sep 1.
Coronavirus disease 2019 (COVID-19) is a novel, highly transmittable and severe strain disease, which has rapidly spread worldwide. Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation (AF), the most prevalent arrhythmia in clinical practice. Here, we review the available evidence for prevalence and incidence of AF in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss disease management approaches and potential treatment options for COVID-19 infected AF patients.
2019冠状病毒病(COVID-19)是一种新型、高传染性的重症疾病,已在全球迅速传播。尽管有流行病学证据表明COVID-19与心血管疾病有关,但对于COVID-19是否以及如何影响心房颤动(AF)(临床实践中最常见的心律失常)却知之甚少。在此,我们回顾了感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)患者中AF患病率和发病率的现有证据,并讨论了COVID-19感染的AF患者的疾病管理方法和潜在治疗选择。